Literature DB >> 27278003

Intent to treat analysis of in vitro fertilization and preimplantation genetic screening versus expectant management in patients with recurrent pregnancy loss.

Gayathree Murugappan1, Lora K Shahine2, Candice O Perfetto3, Lee R Hickok2, Ruth B Lathi3.   

Abstract

STUDY QUESTION: In an intent to treat analysis, are clinical outcomes improved in recurrent pregnancy loss (RPL) patients undergoing IVF and preimplantation genetic screening (PGS) compared with patients who are expectantly managed (EM)? SUMMARY ANSWER: Among all attempts at PGS or EM among RPL patients, clinical outcomes including pregnancy rate, live birth (LB) rate and clinical miscarriage (CM) rate were similar. WHAT IS KNOWN ALREADY: The standard of care for management of patients with RPL is EM. Due to the prevalence of aneuploidy in CM, PGS has been proposed as an alternate strategy for reducing CM rates and improving LB rates. STUDY DESIGN, SIZE, DURATION: Retrospective cohort study of 300 RPL patients treated between 2009 and 2014. PARTICIPANTS/MATERIALS, SETTING,
METHODS: Among two academic fertility centers, 112 RPL patients desired PGS and 188 patients chose EM. Main outcomes measured were pregnancy rate and LB per attempt and CM rate per pregnancy. One attempt was defined as an IVF cycle followed by a fresh embryo transfer or a frozen embryo transfer (PGS group) and 6 months trying to conceive (EM group). MAIN RESULTS AND THE ROLE OF CHANCE: In the IVF group, 168 retrievals were performed and 38 cycles canceled their planned PGS. Cycles in which PGS was intended but cancelled had a significantly lower LB rate (15 versus 36%, P = 0.01) and higher CM rate (50 versus 14%, P < 0.01) compared with cycles that completed PGS despite similar maternal ages. Of the 130 completed PGS cycles, 74% (n = 96) yielded at least one euploid embryo. Clinical pregnancy rate per euploid embryo transfer was 72% and LB rate per euploid embryo transfer was 57%. Among all attempts at PGS or EM, clinical outcomes were similar. Median time to pregnancy was 6.5 months in the PGS group and 3.0 months in the EM group. LIMITATIONS, REASONS FOR CAUTION: The largest limitation is the retrospective study design, in which patients who elected for IVF/PGS may have had different clinical prognoses than patients who elected for expectant management. In addition, the definition of one attempt at conception for PGS and EM groups was different between the groups and can introduce potential confounders. For example, it was not confirmed that patients in the EM group were trying to conceive for each month of the 6-month period. WIDER IMPLICATIONS OF THE FINDING: Success rates with PGS are limited by the high incidence of cycles that intend but cancel PGS or cycles that do not reach transfer. Counseling RPL patients on their treatment options should include not only success rates with PGS per euploid embryo transferred, but also LB rate per initiated PGS cycle. Furthermore, patients who express an urgency to conceive should be counseled that PGS may not accelerate time to conception. STUDY FUNDING/COMPETING INTERESTS: None. TRIAL REGISTRATION NUMBER: N/A. TRIAL REGISTRATION DATE: N/A. DATE OF FIRST PATIENT'S ENROLLMENT: N/A.
© The Author 2016. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  assisted reproduction; expectant management; preimplantation genetic screening; recurrent miscarriage; recurrent pregnancy loss

Mesh:

Year:  2016        PMID: 27278003     DOI: 10.1093/humrep/dew135

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  21 in total

1.  Worldwide live births following the transfer of chromosomally "Abnormal" embryos after PGT/A: results of a worldwide web-based survey.

Authors:  Pasquale Patrizio; Gon Shoham; Zeev Shoham; Milton Leong; David H Barad; Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2019-06-24       Impact factor: 3.412

2.  Preimplantation genetic testing and chances of a healthy live birth amongst recipients of fresh donor oocytes in the United States.

Authors:  Cassandra Roeca; Rachel Johnson; Nichole Carlson; Alex J Polotsky
Journal:  J Assist Reprod Genet       Date:  2020-07-02       Impact factor: 3.412

3.  Improving IVF: is there a limit to our ability to manipulate human biology?

Authors:  Pasquale Patrizio; Sherman Silber
Journal:  J Assist Reprod Genet       Date:  2016-10-28       Impact factor: 3.412

4.  Embryoscopy and karyotype findings of repeated miscarriages in recurrent pregnancy loss and spontaneous pregnancy loss.

Authors:  M Feichtinger; A Reiner; B Hartmann; T Philipp
Journal:  J Assist Reprod Genet       Date:  2018-06-18       Impact factor: 3.412

5.  Transfer the best and biopsy the rest? Blastocyst euploidy rates differ by morphology and day of biopsy.

Authors:  Katherine E McDaniel; Michael S Awadalla; Lynda K McGinnis; Ali Ahmady
Journal:  Arch Gynecol Obstet       Date:  2020-08-17       Impact factor: 2.344

6.  Preimplantation Genetic Testing for Aneuploidy Improves Clinical, Gestational, and Neonatal Outcomes in Advanced Maternal Age Patients Without Compromising Cumulative Live-Birth Rate.

Authors:  Laura Sacchi; Elena Albani; Amalia Cesana; Antonella Smeraldi; Valentina Parini; Marco Fabiani; Maurizio Poli; Antonio Capalbo; Paolo Emanuele Levi-Setti
Journal:  J Assist Reprod Genet       Date:  2019-11-12       Impact factor: 3.412

7.  Decision-making surrounding the use of preimplantation genetic testing for aneuploidy reveals misunderstanding regarding its benefit.

Authors:  Molly M Quinn; Flor Juarez-Hernandez; Molly Dunn; Richard Jason Okamura; Marcelle I Cedars; Mitchell P Rosen
Journal:  J Assist Reprod Genet       Date:  2018-10-18       Impact factor: 3.412

8.  PGT-A: who and when? Α systematic review and network meta-analysis of RCTs.

Authors:  Mara Simopoulou; Konstantinos Sfakianoudis; Evangelos Maziotis; Petroula Tsioulou; Sokratis Grigoriadis; Anna Rapani; Polina Giannelou; Marilena Asimakopoulou; Georgia Kokkali; Amelia Pantou; Konstantinos Nikolettos; Nikolaos Vlahos; Konstantinos Pantos
Journal:  J Assist Reprod Genet       Date:  2021-05-25       Impact factor: 3.357

9.  The impact of preimplantation genetic testing for aneuploidies (PGT-A) on clinical outcomes in high risk patients.

Authors:  Amelia Pantou; Anastasios Mitrakos; Georgia Kokkali; Konstantina Petroutsou; Georgia Tounta; Leandros Lazaros; Alexandros Dimopoulos; Konstantinos Sfakianoudis; Konstantinos Pantos; Michael Koutsilieris; Ariadni Mavrou; Emmanuel Kanavakis; Maria Tzetis
Journal:  J Assist Reprod Genet       Date:  2022-03-25       Impact factor: 3.357

Review 10.  Recent developments in genetics and medically assisted reproduction: from research to clinical applications.

Authors:  J C Harper; K Aittomäki; P Borry; M C Cornel; G de Wert; W Dondorp; J Geraedts; L Gianaroli; K Ketterson; I Liebaers; K Lundin; H Mertes; M Morris; G Pennings; K Sermon; C Spits; S Soini; A P A van Montfoort; A Veiga; J R Vermeesch; S Viville; M Macek
Journal:  Eur J Hum Genet       Date:  2017-12-04       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.